All In Biotech

Drug Trial Radar · NCT04674761

Efficacy and Safety of Odevixibat in Patients With Alagille Syndrome

A Phase 3 Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Odevixibat (A4250) in Patients With Alagille Syndrome (ASSERT)

Last checked: Nov 20, 2026Latest source record: Nov 2, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

52

Actual

Start

Mar 19, 2021

Primary completion

Sep 9, 2022

Study completion Sep 9, 2022

Sponsor

Lead sponsor
AlbireoIndustry
Sponsor type
Industry
First posted
Dec 19, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Double-blind, randomized, placebo-controlled, Phase 3 study to investigate the efficacy and safety of odevixibat compared to placebo in Patients with Alagille Syndrome.

Conditions

  • Alagille Syndrome

Interventions

  • OdevixibatDrug

    Odevixibat is a small molecule and selective inhibitor of IBAT.

  • PlaceboDrug

    Placebo identical in appearance to experimental drug (odevixibat).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Scratching ScoreTime frame: Change from baseline for each four-week average pruritis score to Month 6 (Weeks 21 to 24), in which baseline was calculated based on the 14 days before the start of treatment.

Locations

32 sites in 13 countries. Site status is shown where the registry gives one.

  • University of California - San Francisco

    San Francisco, California

  • Johns Hopkins Hospital

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • Children's Mercy Hospital and Clinics

    Kansas City, Missouri

  • Icahn School of Medicine at Mount Sinai

    New York, New York

  • Columbia University Medical Center

    New York, New York

  • The Childrens Hospital at Montefiore Albert Einstein School of Medicine

    The Bronx, New York

  • Oregon Health Science University School of Medicine

    Portland, Oregon

  • UPMC Children's Hospital of Pittsburgh

    Pittsburgh, Pennsylvania

  • Cliniques Universitaires Saint-Luc Bruxelles

    Brussels, Belgium

  • CHU Sainte-Justine

    Montreal, Quebec, Canada

  • Hôpital Femme Mère Enfant de Lyon

    Bron, France

  • Antenne pédiatrique du CIC - Hopital Jeanne De Flandre

    Lille, France

  • APHM

    Marseille, France

  • Hopital Necker Enfants Malades

    Paris, France

  • Charité-Universitätsmedizin Berlin

    Berlin, Germany

  • Medizinische Hochschule Hannover

    Hanover, Germany

  • Universitätsklinik für Kinder-und Jugendmedizin Tübingen

    Tübingen, Germany

  • Sharie Zedek

    Jerusalem, Israel

  • Schneider Children's Medical Center of Israel

    Petah Tikva, Israel

  • ASST Papa Giovanni XXIII

    Bergamo, Italy

  • AOU Meyer

    Florence, Italy

  • Azienda Ospedale Università Padova

    Padova, Italy

  • Bambino Gesù Children's Hospital

    Rome, Italy

  • University of Malaya Medical Centre

    Kuala Lumpur, Malaysia

  • Universitair Medisch Centrum Groningen (UMCG)

    Groningen, Netherlands

  • University Medical Centre Utrecht, WKZ

    Utrecht, Netherlands

  • Starship Child Health

    Auckland, New Zealand

  • Instytut Pomnik-Centrum Zdrowia Dziecka

    Warsaw, Poland

  • Hacettepe Üniversitesi İhsan Doğramacı Çocuk Hastanesi

    Ankara, Turkey (Türkiye)

  • Istanbul University Medical Faculty Hospital

    Fatih, Turkey (Türkiye)

  • King's College Hospital

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.